Effect of Spironolactone and Potassium Canrenoate on Cytosolic and Nuclear Androgen and Estrogen Receptors of Rat Liver

ANTONIO FRANCAVILLA, ALFREDO DI LEO, PATRICIA K. EAGON, LORENZO POLIMENO, FRANCESCO GUGLIELMI, GIUSEPPE FANIZZA, MICHELE BARONE, and THOMAS E. STARZL

Departments of Gastroenterology and Obstetrics and Gynecology, University of Bari, Bari, Italy; Departments of Medicine and Surgery, University of Pittsburgh, School of Medicine, and Veterans Administration Medical Center, Pittsburgh, Pennsylvania

Spironolactone and potassium canrenoate are diuretics that are used widely for management of cirrhotic ascites. The administration of spironolactone frequently leads to feminization, which has been noted less frequently with the use of potassium canrenoate, a salt of the active metabolite of spironolactone. The use of these two drugs has been associated with decreases in serum testosterone levels and spironolactone with a reduction in androgen receptor (AR) activity. This decrease in AR has been cited as the cause of the antiandrogen effect of these drugs. We therefore assessed the effect of both drugs on levels of androgen and estrogen receptors (ER) in the liver, a tissue that is responsive to sex steroids. Three groups of male rats (n = 12 rats each) were studied. Group 1 (control) received vehicle only; group 2 received spironolactone (5 mg/day); group 3 received potassium canrenoate (5 mg/day). After 21 days of treatment, the animals of all groups were killed and liver tissue was assayed for nuclear and cytosolic AR and ER, and for male specific estrogen binder (MEB), an androgen-responsive protein. Both drugs drastically decreased the nuclear AR content, as compared with the control group, but only spironolactone decreased cytosolic AR. When the total hepatic content of AR is considered, a highly significant decrease is observed only in rats treated with spironolactone. This reduction in hepatic AR content suggested loss of androgen responsiveness of liver. We confirmed this by assessing levels of MEB, and found that livers from group 2 animals had no detectable MEB activity, whereas livers from both group 1 and 3 had normal MEB activity. No changes were observed in nuclear ER and cytosolic ER of group 3 as compared with group 1. Nuclear estrogen receptor decreased and cytosolic ER increased in group 2, but with no change in total ER content. These results indicate that (a) only spironolactone appears to act as an antiandrogen in liver, resulting in a decrease in both AR and male specific estrogen binder content, and (b) neither drug results in elevated hepatic ER content, although spironolactone-treated animals show an altered subcellular localization.

It has been demonstrated by several lines of evidence that liver is an organ responsive to sex hormones. Estrogen receptors (ER) and androgen receptors (AR) have been characterized in the cytosol and nuclei of liver of several animal species and in humans (1–13). The level of these receptors in the liver is dependent to a great extent on the plasma level of the specific hormone, but growth hormone appears to be critical in the regulation of sexual dimorphism of liver function as well. The resultant masculine or feminine pattern of steroid receptors and steroid metabolizing enzymes has an important role in maintaining the sex hormone homeostasis particular to that sex (11,12,14).

Abbreviations used in this paper: AR, androgen receptor; ER, estrogen receptor; [3H]R1881, 17α-methyl-[3H]methyltrienolone; MEB, male specific estrogen binder.
Spironolactone and the potassium salt of its active metabolite potassium canrenoate are two drugs used frequently in chronic hepatic disease and to varying extents have been found to lead to feminization, impotence, and decrease of libido in male patients (15–19). These side effects appear to be less frequent with use of potassium canrenoate than with spironolactone (20,21). Different explanations have been offered for the hormonal changes induced by these drugs, and spironolactone in particular. These include reduction in testosterone synthesis (22,23), increase in testosterone clearance (23), reduction of 5α-reductase activity (24), and interference with AR activity (25). To date, no report has defined the mechanisms of feminization by these two drugs. We report here the effect of spironolactone and potassium canrenoate treatment on the sex hormone receptor and androgen responsive protein status of the liver and the effects of these treatments on serum estrogen and testosterone levels.

Materials and Methods

Animals

Three groups of adult male Sprague–Dawley rats (240 g) were studied. Animals in the control group (group 1) were injected intraperitoneally with 0.5 ml of a solution of physiologic saline with Tween 80 (0.1% vol/vol). The rats in the other groups received 5 mg of spironolactone (group 2) or 5 mg of potassium canrenoate (group 3) dissolved in the same vehicle. All animals were injected daily for 21 days, and killed by decapitation after that time.

Materials

Spironolactone and potassium canrenoate were from SPA, Milano, Italy. Radioactive [2, 4, 6, 7, 16, 17]-[3H]estradiol ([3H]E2), 131 Ci/mmol; 17α-methyl-[3H]methyltrienolone ([3H]R1881), 79 Ci/mmol; and non-radioactive R1881 were obtained from New England Nuclear, Boston, Mass. The radiolabeled steroids used in these studies were assayed periodically for purity by thin-layer chromatography on silica gel G in ethyl acetate/hexane/ethanol (85:10:5), and were used only if purity was >95%. The sources of other materials have been described elsewhere (26,27).

Androgen Receptor Studies

Cytosolic and nuclear fractions were prepared as noted in Reference 28. Cytosolic androgen binding was quantitated using the multiple-point [3H]R1881 (0.2–5.0 nM [3H]R1881) binding assay described in detail previously (26,28). Characterization of the [3H]R1881 binding activity as a cytosolic AR has been reported elsewhere (10,12,28). No metabolism of [3H]R1881 could be detected under our incubation conditions. Because of the large number of animals used in these experiments, the one-point assay described previously (26,28,29) was used to quantitate nuclear AR rather than multiple-point analysis. The validity of this assay has been described previously; values obtained from the one-point assay agree well with those from multiple-point assay (29). Evidence that [3H]R1881 binding represents nuclear AR has been described elsewhere (10,28).

Assay of Androgen-Responsive Male Estrogen Binding Protein

Assays for the determination of cytosolic content of a male-specific estrogen binder (MEB) have been described previously (27). Briefly, cytosol is preincubated for 1 h at 0°C with 500 nM diethylstilbestrol to block ERs. The cytosol is then incubated with 5 nM [3H]E2, [3H]estradiol in the absence and presence of several concentrations (5 nM–5 μM) of unlabeled estradiol for 2 h at 0°C. Bound and free steroid are separated by centrifuge-assisted BioGel P-6 chromatography (27). This assay is quantitative for MEB and is linear over a broad range of protein concentrations. A typical saturation curve analysis is illustrated in Figure 1 of Reference 27.

Estrogen Binding Studies

The protamine sulfate precipitate method used to assay cytosolic ER and the exchange assay used to measure nuclear ER were identical to those described previously (26,28,29).

Other Methods

Protein concentrations were determined by the method of Bradford (30). Deoxyribonucleic acid concentrations of homogenates and nuclear preparations were determined by the method of Burton (31). Corrections for receptor content expressed on the basis of wet weight of liver, and assessment of purity of subcellular fractions have been described previously (29). Serum testosterone, estradiol, and other hormones were determined by specific radioimmunoassays as described previously (32). Equilibrium dissociation constants and the concentration of cytosolic binding sites for receptor and MEB activity were calculated by the method of Scatchard (33). Unweighted linear regression analysis of Scatchard plots was performed on a TILS-III calculator (Texas-III Instruments, Inc., Dallas, Tex.). Statistical analyses were performed using the Student's t-test program available on the Hewlett-Packard 9815S (Hewlett-Packard, Co., Palo Alto, Calif.). All results are expressed as mean ± SD.

Results

Table 1 shows the levels of several gonadal and pituitary hormones in the blood of control rats and those treated with spironolactone and potassium canrenoate. In those animals treated with spi-
Diuretics and Hepatic Steroid Receptors

Table 1. Plasma Hormone Levels in Control Rats and in Rats Treated With Spironolactone and Potassium Canrenoate

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Control group 1</th>
<th>Spironolactone group 2</th>
<th>Potassium canrenoate group 3</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone (ng/ml)</td>
<td>1.8 ± 0.32</td>
<td>0.80 ± 0.24</td>
<td>&lt;0.05</td>
<td>1.5 ± 0.30</td>
</tr>
<tr>
<td>Estradiol (pg/ml)</td>
<td>9.8 ± 1.2</td>
<td>7.9 ± 2.1</td>
<td>NS</td>
<td>9.6 ± 1.1</td>
</tr>
<tr>
<td>Estril (ng/ml)</td>
<td>1.26 ± 0.48</td>
<td>1.68 ± 0.69</td>
<td>NS</td>
<td>1.18 ± 0.39</td>
</tr>
<tr>
<td>Progesterone (ng/ml)</td>
<td>3.93 ± 0.27</td>
<td>3.21 ± 0.53</td>
<td>NS</td>
<td>2.71 ± 0.38</td>
</tr>
<tr>
<td>DHEAS (ng/ml)</td>
<td>9.60 ± 22.3</td>
<td>165.0 ± 22.4</td>
<td>NS</td>
<td>38.6 ± 13.3</td>
</tr>
<tr>
<td>FSH (mU/ml)</td>
<td>1.75 ± 0.34</td>
<td>2.46 ± 0.37</td>
<td>NS</td>
<td>1.19 ± 0.25</td>
</tr>
<tr>
<td>PRL (mU/ml)</td>
<td>7.02 ± 0.77</td>
<td>6.8 ± 0.3</td>
<td>NS</td>
<td>5.95 ± 0.60</td>
</tr>
<tr>
<td>LH (mU/ml)</td>
<td>6.52 ± 1.02</td>
<td>4.76 ± 0.8</td>
<td>NS</td>
<td>4.93 ± 0.93</td>
</tr>
</tbody>
</table>

DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; NS, not significant; PRL, prolactin. Group 1 was treated with vehicle. The other groups received spironolactone (group 2) and potassium canrenoate (group 3) at the dosage of 5 mg/day for 21 days. Values are expressed as mean ± SD. * Values that differ from control values.

In spironolactone-treated animals, there is a significant decrease in testosterone levels; all other hormone levels in this group are comparable to those of the control animals. In those treated with potassium canrenoate, no change was observed in either testosterone or estradiol levels, although significant reductions in progesterone and dehydroepiandrosterone sulfate were found.

Figure 1 reports the activity and subcellular distribution of AR in the livers of these animals. Cytosolic AR levels (Figure 1C) are significantly higher in those rats treated with potassium canrenoate than in either the control animals or the animals treated with spironolactone. There were no variations in the affinity of the cytosolic AR for its ligand in any groups studied. Specifically, the equilibrium dissociation constant values for cytosolic AR were 0.26 ± 0.06, 0.25 ± 0.08, and 0.31 ± 0.04 nM for groups 1, 2, and 3, respectively. The activity of nuclear AR, however, presents a markedly different picture, and is significantly decreased in the animals treated with either spironolactone or potassium canrenoate (Figure 1B). As a result of these variations, the total AR content of the liver (Figure 1A) changed significantly only in those animals treated with spironolactone (50% decrease from normal levels). Interestingly, the activity of total AR in the spironolactone-treated animals shows a decrease proportional to that of plasma testosterone (Figure 1D).

Because total hepatic AR activity and plasma testosterone values were reduced in the spironolactone-treated animals, the activity of a hepatic androgen responsive protein, a MEB, was also assessed. Figure 2 shows that the activity of this protein is undetectable in the livers of those animals treated with spironolactone; this loss of MEB activity is actually higher than that observed in the control rats.

The loss of expression of MEB after spironolactone treatment suggests that this drug may be interfering with androgen action. To determine whether either of these drugs might interfere by competing for androgen binding to its receptor, we tested whether they were capable of competing for AR binding in an in vitro assay. As shown in Figure 3, spironolactone, at a 100-fold and 1000-fold excess, is partially effective as a competitor for [3H]R1881 binding in rat liver.
cytosol. The strong androgens R1881 and dihydrotestosterone, however, are much more effective competitors than is spironolactone. In contrast, potassium canrenoate is incapable of competing for [3H]R1881 binding at any concentration tested. When these substances were tested at 100-fold excess using nuclear preparations, the competition observed was virtually identical to that for the cytosolic AR except that, in nuclei, dihydrotestosterone was equivalent to R1881 in effectiveness.

In other studies, the activity and subcellular distribution of hepatic estrogen receptors in the three groups of animals were examined. The activity of cytosolic ER was virtually unchanged among the three groups (group 1, 445 ± 61; group 2, 553 ± 150; group 3, 441 ± 94 fmol/g liver), nor did the affinity of cytosolic ER for estradiol vary among the groups of animals (equilibrium dissociation constant values of 0.26 ± 0.07, 0.45 ± 0.12, and 0.36 ± 0.08 nM for groups 1, 2, and 3, respectively). The activity of nuclear ER was decreased significantly (p < 0.05) only in that group of animals treated with spironolactone (178 ± 44, 67.2 ± 16, and 209 ± 44 fmol/g liver for groups 1, 2, and 3, respectively). However, the total hepatic ER content does not vary in the three groups of animals studied (group 1, 673 ± 113; group 2, 600 ± 88; and group 3, 650 ± 90 fmol/g liver). This latter finding is consistent with the similar plasma estradiol values in these three groups of animals (Table 1).

Discussion

Liver is a sex steroid-responsive organ in both male and female animals. Many biochemical events, particularly those regarding drug and sex hormone metabolism, are influenced by the sex of the animal. This sexual dimorphism of liver function has been observed in both animals and humans [reviewed in Reference 11]. In male rats, androgen is the major determinant of the masculine pattern of liver function. Androgen stimulates the expression of both androgen receptor and certain enzymes and proteins such as MEB (10,12). This masculine pattern can be feminized by certain changes in serum hormone levels occurring after castration (10,12), chronic alcohol ingestion (5), estrogen treatment (34), and portal vein ligation (35), and during liver regeneration (26,29).

It is known from the clinical literature that spironolactone has feminizing action. There have been many reports addressing the mechanism of this action. Menard et al. (22) demonstrated, in several species, that spironolactone treatment decreases the microsomal cytochrome P450 content of the testes and reduces the activity of 17-hydroxylase, an enzyme necessary for testosterone synthesis. In women treated with spironolactone to reduce hirsutism, this drug has been shown to increase testosterone clearance (23) and decrease genital skin fibroblast steroid 5α reductase (24). Loriaux et al. (36) showed, using an in vitro assay, that spironolactone inhibits the binding of dihydrotestosterone to the AR. Chopra et al. (37) reported that in general such feminization is a result of an alteration of testosterone-estrogen balance.
Our results present further observations on the action of spironolactone. Administration of this drug resulted in a significant decrease in plasma of testosterone levels and hepatic AR and the complete loss of activity of the androgen responsive hepatic protein MEB. As we have reported previously (4,12,27), MEB is a cytosolic protein that has a moderate affinity for estradiol, high binding capacity, and specificity for steroidal estrogen. Its function in the cytosol of male rats is unknown, but may be that of an intracellular estrogen scavenger (4,27). The complete disappearance of MEB in rats treated with spironolactone is significant because, first, its loss represents interruption of hepatic androgen response, and second, its absence might lead to an increased intracellular estrogen concentration.

The loss of MEB only in the spironolactone-treated animals is interesting, as both drug groups demonstrated reduced nuclear AR levels. However, only the spironolactone group demonstrated reduced serum testosterone. It is possible that the nuclear AR has either a higher affinity in vivo for spironolactone than for testosterone, or the spironolactone is available at much higher concentrations than testosterone to interact with the nuclear AR. Because we did not measure serum levels of either drug, it is not possible to differentiate between these possibilities. It is clear, however, that the presence of spironolactone inhibits the expression of MEB; this reduced expression is likely to result from an unproductive interaction of the drug with AR.

In spite of the loss of MEB activity, our results display no action of spironolactone either on plasma estradiol or estriol content, or on the total ER activity in liver. It is possible that our treatment period was too short to produce a feminization of (i.e., an increase in) these activities. It is more likely, however, that in liver disease patients, feminization occurs because spironolactone treatment interferes in maintaining the androgenic influence necessary to sustain a masculine pattern of liver function. Such interference, coupled with an already compromised ability to excrete estrogens, may permit full feminization of liver and other peripheral tissues, such as the breast. However, our experimental animals display no liver disease; thus, treatment of normal male animals with spironolactone may not result in the pronounced feminization that has been noted in some patients with liver disease.

Our results in animals treated with potassium canrenoate, the major active metabolite of spironolactone, confirmed the clinical data indicating that this drug has less antiandrogenic effect than spironolactone. Use of potassium canrenoate has been shown to reverse the gynecomastia produced during treatment with spironolactone (20,38), and shows a much lower incidence of the feminizing side effects of cirrhotic patients (38). It has been demonstrated, in castrated animals, that potassium canrenoate does not inhibit cytochrome P450, as does spironolactone, and produces significantly less antiandrogenic antagonism (39). Thus, our results in animals chronically treated with potassium canrenoate confirm the clinical findings. In fact, no decrease of plasma testosterone, total hepatic AR, or MEB, and no inhibition of androgen binding to its receptor were found to occur in the liver of these animals. Although no decrease was observed in these androgen-related functions, it was noted that potassium canrenoate also resulted in a decrease in nuclear AR. Perhaps the normal serum testosterone in these animals was sufficient to maintain an adequate androgenic response in spite of the reduced nuclear AR levels. Another possibility is that this drug somehow promotes release of the nuclear AR into the cytosolic fraction. The latter possibility is consistent with our findings of increased cytosolic AR in these animals.

In conclusion, the data reported in this paper demonstrate that spironolactone treatment of male rats decreased plasma testosterone and exhibited a powerful anti androgenic effect, as documented by the low levels of hepatic AR and disappearance of an androgen responsive hepatic protein, MEB. We also demonstrated that potassium canrenoate did not show any of the antiandrogenic actions of spironolactone in the liver, suggesting that the clinical improvement reported in patients treated with potassium canrenoate as compared with spironolactone is the result of this biochemical difference. Also, our results indicate that in animals with no underlying liver disease, there is no increase in plasma estrogen levels or total hepatic ER content.

**References**


